Lipocine Inc.
LPCN
Rank in Stocks
#27644
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development... Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Share Price
$1.72
Last synced: 2026-11-09
Market Cap
$14.18M
Change (1 day)
9.55%
Change (1 year)
-40.48%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lipocine Inc. (LPCN)
Category
Healthcare
Operating Margin for Lipocine Inc. (LPCN)
Operating Margin as of November 2026 TTM: -800.82%
According to Lipocine Inc.'s latest financial reports, its current operating margin (TTM) is -800.82%. At the end of 2025 the company had an operating margin of -524.69%.
Operating Margin history for Lipocine Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -800.82% | 52.63% |
| 2025 | -524.69% | 4,989.14% |
| 2024 | -10.31% | -101.64% |
| 2023 | 628.98% | -125.95% |
| 2022 | -2,423.88% | -12,536.53% |
| 2021 | 19.49% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -7,818.83% | 195.49% |
| 2018 | -2,646.03% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | 50.29% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.81% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Lipocine Inc.'s operating margin
What is Lipocine Inc.'s operating margin?
Lipocine Inc.'s operating margin is -800.82%, as of Nov 2026.
What was Lipocine Inc.'s operating margin in 2025?
In 2025, Lipocine Inc.'s operating margin was -524.69%, compared with -10.31% in 2024.
How has Lipocine Inc.'s operating margin changed since 2020?
From 2020 to 2025, Lipocine Inc.'s operating margin was highest in 2023 (628.98%) and lowest in 2022 (-2,423.88%).
How does Lipocine Inc.'s operating margin compare with similar companies?
Lipocine Inc.'s operating margin (-800.82%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.